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Tiwari P1, Mothe R2, Malhotra S3 
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OBJECTIVES: The prophylactic use of antimicrobial agents is recommended for 
the prevention of a variety of post-operative infections, which represent 25% of 
all nosocomial infections in hospitals. Inappropriate antimicrobial prophylaxis 
adds to the pressure on microbial ecology within the hospital, and increases the 
risk of antimicrobial resistance. Several factors can account for ‘antimicrobial 
inappropriateness’. The aim of this study was to evaluate the appropriateness of 
surgical antimicrobial prophylaxis in a private tertiary care hospital. METHODS: 
The data on surgical prophylactic antimicrobial utilization was collected 
retrospectively from Surgical Intensive Care Unit (SICU), Surgical orthopaedic 
ICU-1 (SPICU-1), Surgical orthopaedic ICU-2 (SPICU-2), Neuro Surgery ICU (NSICU) 
and Obstetric ward (gynae surgery). The assessment was done on the basis of 
choice of antibiotic, the time it was administered and the duration for which it 
was given, in accordance with the hospital guidelines. RESULTS: A total number 
of 478 patients were analyzed in different surgical ICUs and Obstetric ward. The 
percentage of appropriateness in selecting antibiotics was found to be 98.5% in 
SPICU-2, followed by 84.6% in NSICU, 74.5% in SPICU-1, 71.6% in SICU and least in 
Obstetric ward with 52.6%. The timing of antibiotic administration was best in 
SICU (83% appropriateness) and least in Obstetric ward (26% appropriateness). 
The appropriate duration of prophylaxis was found to be 100% in SPICU-1 and 
Obstetric ward, while inappropriate duration of prophylaxis 96.6% in SPICU-2. 
CONCLUSIONS: Overall the percentage of appropriate selection of AMAs and 
their timing of administration was fair. The appropriateness of surgical 
prophylaxis with respect to duration was best in SPICU-1 and Obstetric ward. 
These results are encouraging and will help the hospital to achieve ‘completely 
appropriate’ surgical prophylaxis.  
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RECEIPT OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND 
ANGIOTENSIN RECEPTOR BLOCKERS AMONG MEDICARE BENEFICIARIES WITH 
DIABETES AND HYPERTENSION  
Surbhi S, Wang J 
The University of Tennessee Health Science Center, Memphis, TN, USA  
OBJECTIVES: One medication adherence measure for Medicare Part D programs 
by Centers for Medicare and Medicaid Services is the receipt of angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker (ACE/ARB) among 
patients with diabetes and hypertension. The objectives of this study were: 1) To 
determine the rate of receiving ACE/ARB among Medicare beneficiaries  
with diabetes and hypertension, and 2) To identify the predictors of receiving 
ACE/ARB in this population. METHODS: The study population was Medicare 
beneficiaries diagnosed with diabetes and hypertension from the National 
Ambulatory Medical Care Survey and National Hospital Ambulatory Medical  
Care Survey-Outpatient Department, from 2007 to 2009. Predictors of receiving 
ACE/ARB were determined using bivariate and multivariate logistic regression 
analysis. The Andersen's Behavioral Model of Health Services Utilization was 
used to identify patient characteristics for the multivariate analysis. RESULTS: Of 
the 6311 Medicare outpatient and physician office visits with a diagnosis of 
hypertension and diabetes, 40.7% visits received an ACE/ARB. Bivariate analysis 
found higher rate of receiving ACE/ARB for visits made to primary care physician 
compared to non-primary care physician visits (62.9% vs. 37.1%; P<0.05). 
Adjusted multivariate analyses indicated that patient visits made to the primary 
care physicians were more likely to receive ACE/ARB compared to non-primary 
care physician visits (Odds Ratio [OR]: 1.96; 95% Confidence Interval [CI]: 1.59-
2.43), and visits by patients belonging to zip codes with median household 
income within Quartile 2 ($32,794-$40,626), were more likely to receive ACE/ARB 
compared to visits by patients belonging to zip codes with median household 
income within Quartile 1 (< $32,793, OR: 1.45; 95% CI: 1.13-1.87). CONCLUSIONS: 
Fewer than half of the outpatient visits by Medicare beneficiaries with diabetes 
and hypertension received ACE/ARB. Promoting evidence-based medicine and 
increasing access to primary care may have the potential to increase the rates of 
receiving ACE/ARB for Medicare beneficiaries with diabetes and hypertension.  
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IN ATRIAL FIBRILLATION: DEVELOPMENT OF COVERAGE DECISION 
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OBJECTIVES: With the introduction of new methods such as indirect comparison 
and complex economic modeling, the presentation of evidence on effectiveness, 
safety and cost effectiveness to decision makers, who have different levels of 
understanding of these methods, can be challenging. The CCNMA developed a 
framework for presenting such complex evidence from a report on New Oral 
Anticoagulants (NOACs) versus Warfarin for Stroke Prevention in Atrial Fibrillation. The 
purpose of the framework is to provide a concise summary of best available 
research evidence to inform judgments about reimbursement recommendations. 
METHODS: A systematic review of the effects of NOACs compared to warfarin 
was performed using standard Cochrane methods. This information was used to 
conduct adjusted indirect comparisons (i.e. Bayesian mixed-treatment 
comparison network meta-analysis), which were used in an economic evaluation 
to assess cost effectiveness. The effect estimates and assessments of the 
certainty of the evidence for each outcome were summarized in GRADE evidence 
profiles (using GRADEpro 3.6). This information together with results of the 
economic evaluation were summarized in frameworks for coverage decisions. 
This was done in collaboration with the GRADE Working Group and the DECIDE 
project. The frameworks also included information about the severity of the 
condition being treated, the relative importance of outcomes, the total cost 
(impact on budget), impacts on health inequities, and inappropriate use. In 
addition, the frameworks include judgments about each criterion, judgment 
about the overall balance of the desirable and undesirable consequences, 
justification for the recommendation, and implementation considerations. 
RESULTS: The frameworks were used for making reimbursement 
recommendations. CONCLUSIONS: Decision frameworks have the potential to 
provide understandable summaries of complex analyses to inform coverage 
decisions, to help ensure that key criteria are considered, to structure discussion 
and identify reasons for disagreements, and to make the basis for decisions 
transparent to those affected.  
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CHARGE OF CATHETER ABLATION FOR PATIENTS WITH ATRIAL FIBRILLATION: 
EVIDENCE FROM A KEY INFORMANT INTERVIEW IN CHINA  
Liu B, Yang H, Gao Y 
School of Public Health, Fudan University, Shanghai, China  
OBJECTIVES: The charge of catheter ablation for patients with atrial fibrillation 
(AF) in China remains unclear. The purpose of the current study was to examine 
the charge of catheter ablation for AF patients in top AF treatment centers across 
China. METHODS: The study was based on a key informant interview. Key 
informants were selected from 11 top AF treatment centers across 8 provinces of 
China. A total of 22 key informants were interviewed during the period between 
April 2011 and August 2011. Half of the key informants were senior AF specialists 
knowledgeable of catheter ablation, relevant nurses and staffs of hospital’s 
medical insurance office accounting for the other half. The interview was 
conducted face to face by trained interviewer based on an interview outline 
focusing on the charge and related issues. Analysis of interview results followed 
standard qualitative analysis methods. RESULTS: Operation of catheter ablation 
for AF patients grew quickly since 2008 and the related clinical path was issued 
by the Ministry of Health of China in 2010. However, the charge of catheter 
ablation for AF patients varied largely across the selected AF treatment centers 
with a range of RMB 45,000 to 80,000 (i.e., around USD 7200 - 12800). Catheter 
itself was not well included in the current government-valorized list. Charge 
from those government-valorized items accounted for under 10% of total charge 
in most of AF treatment centers, which was associated with heavy cross-
subsidization from the independent charge of catheters not packed in the 
government-valorized items. The choice of catheters was the key contributor to 
the variation of total charge. Charge of the second catheter ablation for recurrent 
AF also varied greatly because of catheter reuse. CONCLUSIONS: The current 
large variation of the charge of catheter ablation for AF patients in China was not 
very much in tandem with the issuance of clinical path and needs to be 
improved.  
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CHARACTERIZING MEDICATION FILLS THROUGH LINKED ADMINISTRATIVE 
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OBJECTIVES: Recent studies have demonstrated that up to 30% of patients never 
fill an initial prescription for antihypertensive medication. This high rate of 
primary nonadherence has direct implications for the outcomes of clinical care. 
Dramatic improvements in the availability of administrative pharmacy claims in 
the electronic health record (EHR) may promote the identification of 
nonadherent patients. The objective of this study was to characterize pharmacy 
fill patterns for a newly prescribed antihypertensive. METHODS: We conducted a 
retrospective cross-sectional study on patients prescribed a new 
antihypertensive within a large primary care practice network from 2011-2012. 
Patients were included if they had a diagnosis of hypertension or elevated blood 
pressure at the time of the new prescription and at least one practice visit within 
the previous 18 months. We excluded patients who did not have an imported 
pharmacy fill history on or after the antihypertensive index date. Pharmacy fill 
claims were pulled for the subsequent 90 days after the index date. All fills of the 
antihypertensive were then linked to the antihypertensive as found in the EHR. 
RESULTS: A total of 131 patients and 133 medications were studied. Average age 
(SD) was 55.4 (14.9), 74.8% were female, 26.7% were black and 32.8% were white. 
Most patients were prescribed one antihypertensive; 2 patients were prescribed 
two. Of the medications studied, 112 medications were linked to a fill from the 
pharmacy claims. Of the linked medications, 73.2% were filled on the index date. 
Average number of days (SD) to first fill was 4.6 (12.1); 94.6% of linked fills were 
filled within the first 30 days. CONCLUSIONS: Nearly a quarter of patients do not 
fill newly prescribed antihypertensives within 90 days of initial prescription. Our 
preliminary data suggest that the real-time availability of pharmacy claims data 
could be useful to identify nonadherent patients.  
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OBJECTIVES: To identify what was the influence of cardiovascular drugs 
recommendations issued by AOTM in years 2005-2012 for the reimbursement 
decisions taken by Minister of Health (MoH). The main task of AOTM, established 
in 2005, is to prepare recommendations on financing all medical technologies 
from public funds for the MoH. For all new health technologies entering market 
full pharmacoeconomic evaluations are required before the reimbursement 
decisions are taken by MoH METHODS: Among recommendations of AOTM 
published until the end of 2012 we analyzed all related to cardiovascular drugs. 
The recommendations were identified and categorized into types of 
recommendations (positive or negative). We compared the outcomes with 
reimbursement list officially published by MoH (January 2013). RESULTS: Among 
753 documents (recommendations, opinions, statements) issued by AOTM, only 
38 (5%) applied to innovative, cardiovascular drugs. AOTM issued positive 
recommendations for reimbursement to 22 of 38 of cardiovascular drug 
submissions (58%). 16 of 38 (42%) were not approved and received negative 
recommendations. Having analyzed the reimbursement list we realized that only 
10 of 38 (26%) drugs assessed by AOTM are occurred on the reimbursement list. 9 
of 10 drugs(90%) were positive recommended by AOTM. Only 1 drug (10%) was 
assessed negative. CONCLUSIONS: The influence of recommendations issued by 
AOTM for cardiovascular drugs for reimbursement decisions taken by MOH were 
not significant with respect to place the drugs on the list. But we can realize that 
only 1 drug with negative AOTM recommendation exists on the list. The 
conclusion indicates that the medicine with negative recommendations probably 
will not be accepted (in 90%) for reimbursement from public sources. Contrarily, 
not every drug with positive recommendation issued by AOTM will be placed on 
the reimbursement list.  
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OBJECTIVES: This study was performed to evaluate and provide a new positive  
list of antihypertensive drugs for reimbursement in the Korean national health 
insurance. METHODS: First, among total 1,226 items, 360 combination items were 
excluded from this evaluation and 25 essential drug items (ban-on-delisting drugs, 
orphan drugs, emergency drugs, and drugs without any alternatives) were to 
remain on reimbursement list without any evaluation. Next, clinical usefulness was 
evaluated by criteria from medical textbooks, guidelines, and WHO lists, and 1 item 
was to be delisted due to lack of clinical usefulness. In the third step, daily cost  
was calculated. Drugs which belong to bottom 25% in daily cost were defined as 
“relatively low-price drugs,” which could remain on the list without subsequent 
evaluation. Other drugs were to be evaluated by cost-effectiveness. Clinical 
effectiveness was evaluated based on proxy outcomes (blood pressure) and final 
outcomes (mortality, morbidity) by reviewing clinical literatures and 6 assessment 
reports from overseas health technology institutions as well as opinions of clinical 
experts. RESULTS: There was no clear evidence depicting differences in clinical 
effectiveness. Therefore, the prices of hypertension drugs would have to be reduced 
to the lowest level of all hypertension drugs if a cost-minimization principle  
is applied. However, the lowest levels within each class were suggested instead in 
recognition of differences in adverse events and effects on co-morbidity among  
the classes. CONCLUSIONS: It was not proven that a particular class or ingredient 
among hypertensive drugs was superior to others. However, the policy based  
on this result has to be carefully implemented. It is important that practicability, 
fairness, and equity of the result as well as scientific accuracy have to be  
balanced since this type of study is commonly associated with interests of 
stakeholders.  
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COMPARATIVE EFFECTIVENESS RESEARCH ON THE NEW ANTICOAGULANTS- 
IS IT WORTH IT?  
Wisloff T, Hagen G 
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OBJECTIVES: To investigate whether or not elimination of decision uncertainty 
related to the new anticoagulants would be cost-effective, by calculating the 
added value of conducting an RCT comparing the new oral anticoagulants 
(apixaban, dabigatran and rivaroxaban) relative to each other and relative to 
warfarin for stroke prevention in patients with atrial fibrillation. METHODS: We 
developed a decision analytic model, designed as a probabilistic Markov model 
containing 200 different probability distributions. The model included eight 
health states; atrial fibrillation (AF), heart failure, moderate stroke sequela, 
severe stroke sequela, atrial fibrillation with previous acute myocardial 
infarction (AMI), atrial fibrillation with previous stroke, major gastrointestinal 
bleeding and dead. Epidemiological input data was gathered from registries. Data 
on Quality of Life were based on published EQ-5D data and costs were based on 
national tariffs. Efficacy data included the three major randomised controlled 
trials comparing each of the new oral anticoagulants (apixaban, dabigatran and 
rivaroxaban) to warfarin. Current efficacy estimates indicate that the new 
anticoagulants are efficacious on some, but not all, outcomes compared to 
warfarin. However, no direct evidence comparing any of these new 
anticoagulants with each other is yet available. RESULTS: Expected value of 
perfect information analysis on groups of parameters (EVPPI) for efficacy 
parameters was clearly much higher than EVPPI for other parameters (QALYs, 
costs and baseline risk epidemiological data). Population EVPPI for efficacy data 
was $ 1.3 billion in a population of 5 million, given an assumed threshold value 
of $ 100,000 per QALY gained. CONCLUSIONS: There is clearly an added value in 
conducting more research on the efficacy of new oral anticoagulants. Hence, 
new randomized controlled trial(s) comparing all of the new oral anticoagulants 
would probably decrease decision uncertainty considerably.  
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DEMOGRAPHIC AND CLINICAL CHARACTERISTICS, AND TREATMENT OF 
CARDIOVASCULAR RISK FACTORS AMONG U.S. ELDERLY PATIENTS WITH 
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OBJECTIVES: To examine the demographic and clinical characteristics,  
and cardiovascular treatment in patients with high-risk vascular disease (HRVD). 
METHODS: A large employer-based US administrative claims database was used 
to conduct this retrospective cohort study. Patients with HRVD (defined  
as cerebrovascular disease [CVD], coronary artery disease with diabetes [CADD], 
peripheral artery disease [PAD], or history of acute coronary syndrome [ACS] 
[≥30days through 365 days after discharge for ACS]) between October 1, 2008  
to September 30, 2009, ≥65 years of age, were identified with minimum 12-month 
pre- and 24-month post-index health plan eligibility. Patients’ baseline 
demographic characteristics, comorbidities, and medication use were examined 
and compared across groups with and without polyvascular disease. RESULTS: 
There were 525,893 HRVD patients identified with an average age of 77.2  
years and gender of 51.0% male. Of the identified patients, 59.5% had 
hypertension, 32.9% had hypercholesterolemia, and 44.7% had diabetes. Patients 
were generally undertreated with statins (50.3% HRVD; range: 44.9% PAD to 
64.0% CADD), antiplatelets (21.4% HRVD; range: 16.8% CVD to 49.7% ACS), beta-
blockers (41.8% HRVD; range: 35.2% CVD to 67.1% ACS), and other evidence-based 
risk reduction therapies. Patients with >1 affected artery bed (18%) had 
numerically similar age (age: 77.1, 77.6, 77.0 for 1, 2, 3 affected disease beds), but 
had higher cardiovascular risk factors (for 1, 2, 3 affected disease beds, 
hypertension: 57.2%, 69.1%, 73.4%; hypercholesterolemia: 32.0%, 36.6%, 37.3%; 
diabetes: 40.5%, 61.2%, 83.9%), and used more cardiovascular-related 
medications (statins: 48.0%, 59.9%, 67.5%; antiplatelets: 18.3%, 33.8%, 48.8%; beta-
blockers: 39.0%, 53.3%, 64.4%) compared to patients with only 1 affected disease 
bed (p<0.01). The average number of medications per patient was 9.1 for HRVD 
patients, ranging from 7.6 for CVD-alone patients to 17.7 for patients with ACS, 
CADD, CVD, and PAD (N=1456). CONCLUSIONS: In elderly HRVD patients, classic 
cardiovascular risk factors are consistent and common, but are undertreated in 
the U.S.  
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PHYSICIAN'S ADHERENCE TO THE 2009 AHA/ACC GUIDELINES IN ACUTE 
MYOCARDIAL INFARCTION (AMI) IN CARDIAC CARE UNIT OF A PRIVATE 
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OBJECTIVES: Less numbers of studies on cardiovascular diseases were found  
in Indian population. So, the results of present study may helpful in improving 
the consistency and quality of care in the management of AMI in Indian 
population. The objective of this retrospective observational study was to 
evaluate the physicians’ adherence to 2009 American Heart Association (AHA) 
/American College of Cardiology (ACC) guidelines in the management of AMI. 
METHODS: Chi-Square test and student t-test were used for analysing the data. 
The adherence to early and late performance measures was assessed by 
comparing the performance measures actually given to the patients on 
admission and discharge with those recommended by the AHA/ACC guidelines 
for management of AMI. RESULTS: A total of 127 patients’ with confirmed 
diagnosis of AMI were analysed in this observational study. Statistically 
significant difference was found between average ages of male and female 
patients (57.2±1.2, 66±1.7 respectively, P<0.05). The adherence to clinical 
performance measures like aspirin, antithrombin and thrombolytic therapy on 
admission and discharge was found to be 100%. Adequate AMI management was 
seen in 75.9% NSTEMI and 70.4% STEMI patients. No difference in the adequate 
management for AMI was found between STEMI and NSTEMI groups (P>0.05). 
Low adherence was seen for the prescription of b-blocker on discharge in both 
STEMI and NSTEMI patients (83.7%, 86.2% respectively) when compared to other 
performance measures. The adherence to all early performance measures in 
both the groups was found to be good. CONCLUSIONS: The overall adherence to 
early and late performance measures in AMI management in this North Indian 
study population was satisfactory. Adaptation and implementation of clinical 
practice guidelines in any health care sector will increase the consistency and 
quality of care. 
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ANTITHROMBOTIC STRATEGIES IN ACUTE CORONARY SYNDROME AND 
ATRIAL FIBRILLATION: A COMMUNITY PERSPECTIVE  
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OBJECTIVES: Atrial fibrillation (AF) commonly complicates acute coronary 
syndromes (ACS) and selecting antithrombotic regimen for these patients is 
complex. We describe the spectrum of antithrombotic use in a community 
cohort of patients with ACS, and identify predictors of the choice of strategies in 
